A clinical perspective on COVID-19, ACE2 and RAAS inhibition
Lecture 2 out of 3
Video navigation menu
- How the controversy on RAASi use during COVID-19 pandemic started 01:00
- Overriding risks of withdrawal of ACEi/ARBs in COVID-19 patients 03:39
- Potential therapeutic options in COVID-19 07:54
- Take home messages 15:14
- An add-on on sustained treatment with RAASi while obviating hyperkalemia 16:31
The educational objective of this series of 3 videos is to provide cardiovascular physicians with current insights in ACE2 and the use of RAASi in the management of patients with COVID-19.
Murray Epstein, M.D., is emeritus professor of medicine at the Division of Nephrology and Hypertension at the University of Miami Miller School of Medicine, Miami, FL, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
This educational program was sponsored by unrestricted educational grants from Vifor Pharma and Novartis.